Capital Impact Advisors’s Albany Molecular Research Inc AMRI Stock Holding History

Capital Impact Advisors’s Portfolio AMRI Stock Details AMRI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-49,644	Closed	-$931K	–	247
2016 Q4	$931K	Hold	49,644	–	–	0.39%	140
2016 Q3	$820K	Hold	49,644	–	–	0.35%	160
2016 Q2	$667K	Hold	49,644	–	–	0.31%	188
2016 Q1	$759K	Buy	49,644 +27,700	+126%	+$434K	0.36%	183
2015 Q4	$436K	Sell	21,944 -22,000	-50%	-$418K	0.21%	208
2015 Q3	$766K	Hold	43,944	–	–	0.39%	96
2015 Q2	$889K	Hold	43,944	–	–	0.4%	93
2015 Q1	$773K	Buy	43,944 +34,781	+380%	+$593K	0.35%	119
2014 Q4	$149K	Hold	9,163	–	–	0.07%	172
2014 Q3	$202	Hold	9,163	–	–	﹤0.01%	99
2014 Q2	$184K	Buy	+9,163	New	+$155K	0.14%	101

Other funds holding AMRI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PIP

Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return

ACM

American Capital Management New York $1.86B AUM 20.23% 1-Year Est. Return

OWP

Obermeyer Wealth Partners Aspen, Colorado $2.17B AUM 19.33% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

EWM

Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return

Walthausen & Co Malta, New York $120M AUM 2.66% 1-Year Est. Return

Capital Impact Advisors's AMRI Position: Q1 2017 in Review

Capital Impact Advisors sold out of Albany Molecular Research Inc (AMRI) in Q1 2017, closing a stake of 49,644 shares — an estimated $931K sold.

Capital Impact Advisors first reported a position in AMRI in Q2 2014 and held it in 11 quarters. The position peaked at $931K in Q4 2016. 139 funds tracked by Wall St. Rank hold AMRI as of Q1 2017.

Capital Impact Advisors reported no remaining Albany Molecular Research Inc position as of Q1 2017 after selling out during the quarter.
Capital Impact Advisors sold 49,644 Albany Molecular Research Inc shares in Q1 2017, an estimated $931K.
Capital Impact Advisors first reported a position in Albany Molecular Research Inc in Q2 2014 and held it in 11 quarters.
Capital Impact Advisors's Albany Molecular Research Inc position peaked at $931K in Q4 2016.
139 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q1 2017.

Based on Capital Impact Advisors's 13F filing for Q1 2017, filed 19 Apr 2017.